You are here

Article info

Article menu

Download PDFPDF

Oral Presentations
Plenary session 10: Young researcher session
10.01 Prostanoid-insensitive chimeric antigen receptor modified T cells mediate therapeutic efficacy in solid cancer models

Authors

  • J Dörr Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, München, Germany PubMed articlesGoogle scholar articles
  • L Gregor Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, München, Germany PubMed articlesGoogle scholar articles
  • SB Lacher Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), München, Germany PubMed articlesGoogle scholar articles
  • A Öner Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, München, Germany PubMed articlesGoogle scholar articles
  • S Lesch Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, München, Germany PubMed articlesGoogle scholar articles
  • S Michaelides Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, München, Germany PubMed articlesGoogle scholar articles
  • L Majed Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, München, Germany PubMed articlesGoogle scholar articles
  • L Fertig Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, München, Germany PubMed articlesGoogle scholar articles
  • E Carlini Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, München, Germany PubMed articlesGoogle scholar articles
  • D Andreu Sanz Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, München, Germany PubMed articlesGoogle scholar articles
  • D Briukhovetska Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, München, Germany PubMed articlesGoogle scholar articles
  • S Stock Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, München, Germany PubMed articlesGoogle scholar articles
  • A Gottschlich Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, München, Germany PubMed articlesGoogle scholar articles
  • JP Böttcher Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), München, Germany PubMed articlesGoogle scholar articles
  • S Kobold Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, München, Germany German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany PubMed articlesGoogle scholar articles

Citation

Dörr J, Gregor L, Lacher S, et al
10.01 Prostanoid-insensitive chimeric antigen receptor modified T cells mediate therapeutic efficacy in solid cancer models
Journal for ImmunoTherapy of Cancer 2024;12:doi: 10.1136/jitc-2024-ITOC10.6
Online issue publication 
March 20, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.